Compare ELA & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELA | VALN |
|---|---|---|
| Founded | 1965 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.7M | 534.3M |
| IPO Year | 1995 | 2021 |
| Metric | ELA | VALN |
|---|---|---|
| Price | $17.41 | $6.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $16.50 | $16.00 |
| AVG Volume (30 Days) | ★ 166.7K | 144.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.38 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $241,021,362.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.54 | $93.87 |
| P/E Ratio | $30.93 | ★ N/A |
| Revenue Growth | ★ 33.62 | N/A |
| 52 Week Low | $5.33 | $5.43 |
| 52 Week High | $18.29 | $12.25 |
| Indicator | ELA | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 63.56 | 29.06 |
| Support Level | $16.09 | $5.95 |
| Resistance Level | $18.29 | $6.73 |
| Average True Range (ATR) | 0.81 | 0.28 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 57.71 | 32.49 |
Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. It operates through two segments, Consumer and Commercial Services. The Consumer segment, which generates key revenue for the company, predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins, and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.